Vulvovaginal candidosis

Lancet

Volumn 369, Issue 9577, 2007, Pages 1961-1971

  Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BUTOCONAZOLE; CLOTRIMAZOLE; ECONAZOLE; FENTICONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; ORAL CONTRACEPTIVE AGENT; PYRROLE DERIVATIVE; SERTACONAZOLE; TERCONAZOLE; TIOCONAZOLE; VIRULENCE FACTOR;

BEHAVIOR; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DISEASE PREDISPOSITION; HEREDITY; HUMAN; INCIDENCE; INFECTION; MICROBIOLOGY; MICROSCOPY; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; UNITED STATES; VAGINA CANDIDIASIS;

EID: 34249895255     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60917-9     Document Type: Review

References (142)

1. Hurley R., and De Louvois J. Candida vaginitis. Postgrad Med J 55 (1979) 645-647
2. Foxman B., Marsh J., Gillespie B., and Sobel J. Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey. J Womens Health 7 (1998) 1167-1174
3. McCormack Jr. W., Zinner S., and McCormack W. The incidence of genitourinary infections in a cohort of healthy women. Sex Transm Dis 21 (1994) 63-64
4. Berg A., Heidrich F., Fihn S., et al. Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. JAMA 251 (1984) 620-625
5. Eckert L., Hawes S., Stevens C., Koutsky L., Eschenbach D., and Holmes K. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 92 (1998) 757-765
6. Chow A., Percival-Smith R., Bartlett K., Goldring A., and Morrison B. Vaginal colonization with Escherichia coli in healthy women. Determination of relative risks by quantitative culture and multivariate statistical analysis. Am J Obstet Gynecol 154 (1986) 120-126
7. Goldacre M., Watt B., Loudon N., Milne L., Loudon J., and Vessey M. Vaginal microbial flora in normal young women. BMJ 1 (1979) 1450-1455
8. Odds F. Candidosis of the genitalia. Candida and candidosis. A review and bibliography (1988), Bailliere Tindall, London, Philadelphia, Toronto, Sydney, Tokyo 124
9. Beigi R., Meyn L., Moore D., Krohn M., and Hillier S. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 104 (2004) 926-930
10. Foxman B., Barlow R., D'Arcy H., Gillespie B., and Sobel J. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis 27 (2000) 230-235
11. Fleury F. Adult vaginitis. Clin Obstet Gynecol 24 (1981) 407-438
12. Sobel J. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 152 (1985) 924-935
13. Sobel J. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 315 (1986) 1455-1458
14. Landers D., Wiesenfeld H., Heine R., Krohn M., and Hillier S. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol 190 (2004) 1004-1010
15. Corsello S., Spinillo A., Osnengo G., et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 110 (2003) 66-72
16. Okungbowa F., Isikhuemhen O., and Dede A. The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities. Rev Iberoam Micol 20 (2003) 60-103
17. Buscemi L., Arechavala A., and Negroni R. Study of acute vulvovaginitis in sexually active adult women, with special reference to candidosis, in patients of the Francisco J Muniz Infectious Diseases Hospital. Rev Iberoam Micol 21 (2004) 177-181
18. Nyirjesy P., Alexander A., and Weitz M. Vaginal Candida parapsilosis: pathogen or bystander?. Infect Dis Obstet Gynecol 13 (2005) 37-41
19. Singh S., Sobel J., Bhargava P., Boikov D., and Vazquez J. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 35 (2002) 1066-1070
20. Erdem H., Cetin M., Timuroglu T., Cetin A., Yanar O., and Pahsa A. Identification of yeasts in public hospital primary care patients with or without clinical vaginitis. Aust N Z J Obstet Gynaecol 43 (2003) 312-316
21. Holland J., Young M., Lee O., and C-A Chen S. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 79 (2003) 249-250
22. Bauters T., Dhont M., Temmerman M., and Nelis H. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 187 (2002) 569-574
23. Cauwenbergh G. Vaginal candidiasis: evolving trends in the incidence and treatment of non-Candida albicans infection. Curr Probl Obstet Gynecol Fertil 8 (1990) 241
24. Sobel J., Brooker D., Stein G., et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 172 (1995) 1263-1268
25. Sobel J., Wiesenfeld H., Martens M., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 351 (2004) 876-883
26. Lian C., Zhao J., Zhang Z., and Liu W. Genotype of candida species associated with different conditions of vulvovaginal candidosis. Mycoses 47 (2004) 495-502
27. Macura A., Voss A., Melchers W., Meis J., Syslo J., and Heczko P. Characterization of pathogenetic determinants of Candida albicans strains. Zentralbl Bakteriol 287 (1998) 501-508
28. Soll D., Galask R., Isley S., et al. Switching of Candida albicans during successive episodes of recurrent vaginitis. J Clin Microbiol 27 (1989) 681-690
29. King R., Lee J., and Morris A. Adherence of Candida albicans and other candida species to mucosal epithelial cells. Infect Immun 27 (1980) 667-674
30. Sobel J., Myers P., Kaye D., and Levison M. Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis 143 (1981) 76-82
31. Trumbore D., and Sobel J. Recurrent vulvovaginal candidiasis: vaginal epithelial cell susceptibility to Candida albicans adherence. Obstet Gynecol 67 (1986) 810-812
32. Sobel J., Muller G., and Buckley H. Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun 44 (1984) 576-580
33. De Bernardis F., Agatensi L., Ross I., et al. Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J Infect Dis 161 (1990) 1276-1283
34. Al-Hedaithy S. Spectrum and proteinase production of yeasts causing vaginitis in Saudi Arabian women. Med Sci Monit 8 (2002) CR498-CR501
35. Taylor B., Staib P., Binder A., et al. Profile of Candida albicans-secreted aspartic proteinase elicited during vaginal infection. Infect Immun 73 (2005) 1828-1835
36. Naglik J., Rodgers C., Shirlaw P., et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 188 (2003) 469-479
37. Schaller M., Bein M., Korting H., et al. The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect Immun 71 (2003) 3227-3234
38. Shah D., Glover D., and Larsen B. In situ mycotoxin production by Candida albicans in women with vaginitis. Gynecol Obstet Invest 39 (1995) 67-69
39. Moors M., Stull T., Blank K., Buckley H., and Mosser D. A role for complement receptor-like molecules in iron acquisition by Candida albicans. J Exp Med 175 (1992) 1643-1651
40. Slutsky B., Buffo J., and Soll D. High-frequency switching of colony morphology in Candida albicans. Science 230 (1985) 666-669
41. Soll D. High-frequency switching in Candida albicans and its relations to vaginal candidiasis. Am J Obstet Gynecol 158 (1988) 997-1001
42. Chong P., Lee Y., Tan B., and Ng K. Genetic relatedness of candida strains isolated from women with vaginal candidiasis in Malaysia. J Med Microbiol 52 (2003) 657-666
43. Schroppel K., Rotman M., Galask R., Mac K., and Soll D. Evolution and replacement of Candida albicans strains during recurrent vaginitis demonstrated by DNA fingerprinting. J Clin Microbiol 32 (1994) 2646-2654
44. Bertholf M., and Stafford M. Colonization of Candida albicans in vagina, rectum, and mouth. J Fam Pract 16 (1983) 919-924
45. Barousse M., Van Der Pol B., Fortenberry D., Orr D., and Fidel Jr. P. Vaginal yeast colonisation, prevalence of vaginitis, and associated local immunity in adolescents. Sex Transm Infect 80 (2004) 48-53
46. Barousse M., Espinosa T., Dunlap K., and Fidel Jr. P. Vaginal epithelial cell anti-Candida albicans activity is associated with protection against symptomatic vaginal candidiasis. Infect Immun 73 (2005) 7765-7767
47. Fidel Jr. P. History and new insights into host defense against vaginal candidiasis. Trends Microbiol 12 (2004) 220-227
48. Ip W., and Lau Y. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 190 (2004) 632-640
49. Pellis V., De Seta F., Crovella S., et al. Mannose binding lectin and C3 act as recognition molecules for infectious agents in the vagina. Clin Exp Immunol 139 (2005) 120-126
50. Babula O., Lazdane G., Kroica J., Linhares I., Ledger W., and Witkin S. Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 40 (2005) 1258-1262
51. Naidu A., Chen J., Martinez C., Tulpinski J., Pal B., and Fowler R. Activated lactoferrin's ability to inhibit candida growth and block yeast adhesion to the vaginal epithelial monolayer. J Reprod Med 49 (2004) 859-866
52. Auger P., and Joly J. Microbial flora associated with Candida albicans vulvovaginitis. Obstet Gynecol 55 (1980) 397-401
53. Savage D. Microbial interference between indigenous yeast and lactobacilli in the rodent stomach. J Bacteriol 98 (1969) 1278-1283
54. Agnew K., and Hillier S. The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis 22 (1995) 269-273
55. Diamond R., Krzesicki R., and Jao W. Damage to pseudohyphal forms of Candida albicans by neutrophils in the absence of serum in vitro. J Clin Invest 61 (1978) 349-359
56. Ashman R., and Papadimitriou J. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev 59 (1995) 646-672
57. Waldman R., Cruz J., and Rowe D. Immunoglobulin levels and antibody to Candida albicans in human cervicovaginal secretions. Clin Exp Immunol 10 (1972) 427-434
58. de Carvalho R., Cunha C., Silva D., et al. IgA, IgE and IgG subclasses to Candida albicans in serum and vaginal fluid from patients with vulvovaginal candidiasis. Rev Assoc Med Bras 49 (2003) 434-438 (in Portuguese).
59. Cassone A., De Bernardis F., and Torososantucci A. An outline of the role of anti-candida antibodies within the context of passive immunization and protection from candidiasis. Curr Mol Med 5 (2005) 377-382
60. Polonelli L., De Bernardis F., Conti S., et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 152 (1994) 3175-3182
61. Han Y., Morrison R., and Cutler J. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 66 (1998) 5771-5776
62. Fidel Jr. P. Immunity in vaginal candidiasis. Curr Opin Infect Dis 18 (2005) 107-111
63. Wozniak K., Wormley Jr. F., and Fidel Jr. P. Candida-specific antibodies during experimental vaginal candidiasis in mice. Infect Immun 70 (2002) 5790-5799
64. Witkin S., Jeremias J., and Ledger W. Vaginal eosinophils and IgE antibodies to Candida albicans in women with recurrent vaginitis. J Med Vet Mycol 27 (1989) 57-58
65. Carvalho L., Bacellar O., Neves N., de Jesus A., and Carvalho E. Downregulation of IFN-gamma production in patients with recurrent vaginal candidiasis. J Allergy Clin Immunol 109 (2002) 102-105
66. Fidel Jr. P., Barousse M., Espinosa T., et al. An intravaginal live candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 72 (2004) 2939-2946
67. Cenci E., Romani L., Mencacci A., et al. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol 23 (1993) 1034-1038
68. Geiger A., and Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 7 (1996) 182-187
69. Chaim W., Foxman B., and Sobel J. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. J Infect Dis 176 (1997) 828-830
70. Calderon L., Williams R., Martinez M., Clemons K., and Stevens D. Genetic susceptibility to vaginal candidiasis. Med Mycol 41 (2003) 143-147
71. Bland P. Experimental vaginal and cutaneous moniliasis: clinical and laboratory studies of certain monilias associated with vaginal, oral and cutaneous thrush. Arch Dermatol Syphil 36 (1937) 760
72. Cotch M., Hillier S., Gibbs R., and Eschenbach D. Epidemiology and outcomes associated with moderate to heavy candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 178 (1998) 374-380
73. Dennerstein G., and Ellis D. Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol 41 (2001) 326-328
74. Tarry W., Fisher M., Shen S., and Mawhinney M. Candida albicans: the estrogen target for vaginal colonization. J Surg Res 129 (2005) 278-282
75. Powell B. Identification of a 173-estradiol-binding protein in Candida albicans and Candida (Torulopsis) glabrata. Exp Mycology 8 (1984) 304
76. Davidson F., and Oates J. The pill does not cause 'thrush'. BJOG 92 (1985) 1265-1266
77. Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health 80 (1990) 329-331
78. Reed B., Zazove P., Pierson C., Gorenflo D., and Horrocks J. Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. J Womens Health (Larchmt) 12 (2003) 979-989
79. Barbone F., Austin H., Louv W., and Alexander W. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 163 (1990) 510-514
80. Demirezen S., Dirlik O., and Beksac M. The association of candida infection with intrauterine contraceptive device. Cent Eur J Public Health 13 (2005) 32-34
81. Fidel Jr. P., Vazquez J., and Sobel J. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C albicans. Clin Microbiol Rev 12 (1999) 80-96
82. de Leon E., Jacober S., Sobel J., and Foxman B. Prevalence and risk factors for vaginal candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2 (2002) 1-4
83. Goswami R., Dadhwal V., Tejaswi S., et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 41 (2000) 162-166
84. Donders G., Prenen H., Verbeke G., and Reybrouck R. Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 187 (2002) 989-993
85. Spinillo A., Capuzzo E., Acciano S., De Santolo A., and Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol 180 (1999) 14-17
86. Wilton L., Kollarova M., Heeley E., and Shakir S. Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf 26 (2003) 589-597
87. Pirotta M., Gunn J., and Chondros P. "Not thrush again!" Women's experience of post-antibiotic vulvovaginitis. Med J Aust 179 (2003) 43-46
88. Bluestein D., Rutledge C., and Lumsden L. Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV). Fam Pract Res J 11 (1991) 319-326
89. Oriel J., and Waterworth P. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol 28 (1975) 403-406
90. Pultz N., Stiefel U., Ghannoum M., Helfand M., and Donskey C. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob Agents Chemother 49 (2005) 438-440
91. Glover D., and Larsen B. Relationship of fungal vaginitis therapy to prior antibiotic exposure. Infect Dis Obstet Gynecol 11 (2003) 157-160
92. Pirotta M., and Garland S. Genital candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol 44 (2006) 3213-3217
93. Spinillo A., Carratta L., Pizzoli G., et al. Recurrent vaginal candidiasis. Results of a cohort study of sexual transmission and intestinal reservoir. J Reprod Med 37 (1992) 343-347
94. Bradshaw C., Morton A., Garland S., Morris M., Moss L., and Fairley C. Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol 106 (2005) 105-114
95. Neves N., Carvalho L., De Oliveira M., et al. Association between atopy and recurrent vaginal candidiasis. Clin Exp Immunol 142 (2005) 167-171
96. Miles M., Olsen L., and Rogers A. Recurrent vaginal candidiasis. Importance of an intestinal reservoir. JAMA 238 (1977) 1836-1887
97. Thin R., Leighton M., and Dixon M. How often is genital yeast infection sexually transmitted?. BMJ 2 (1977) 93-94
98. Garcia-Tamayo J., Castillo G., and Martinez A. Human genital candidiasis: histochemistry, scanning and transmission electron microscopy. Acta Cytol 26 (1982) 7-14
99. Merson-Davies L., Odds F., Malet R., et al. Quantification of Candida albicans morphology in vaginal smears. Eur J Obstet Gynecol Reprod Biol 42 (1991) 49-52
100. Schaaf V., Perez-Stable E., and Borchardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med 150 (1990) 1929-1933
101. Anderson M., Klink K., and Cohrssen A. Evaluation of vaginal complaints. JAMA 291 (2004) 1368-1379
102. Bergman J., Berg A., Schneeweiss R., and Heidrich F. Clinical comparison of microscopic and culture techniques in the diagnosis of candida vaginitis. J Fam Pract 18 (1984) 549-552
103. Trama J., Adelson M., Raphaelli I., Stemmer S., and Mordechai E. Detection of Candida species in vaginal samples in a clinical laboratory setting. Infect Dis Obstet Gynecol 13 (2005) 63-67
104. Sobel J., Kapernick P., Zervos M., et al. Treatment of complicated candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 185 (2001) 363-369
105. Reef S., Levine W., McNeil M., et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis 20 suppl 1 (1995) S80-S90
106. Watson M., Grimshaw J., Bond C., Mollison J., and Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG 109 (2002) 85-95
107. Tooley P. Patient and doctor preferences in the treatment of vaginal candidosis. Practitioner 229 (1985) 655-660
108. Dellenbach P., Thomas J., Guerin V., Ochsenbein E., and Contet-Audonneau N. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int J Gynaecol Obstet 71 suppl 1 (2000) S47-S52
109. Seidman L., and Skokos C. An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. Infect Dis Obstet Gynecol 13 (2005) 197-206
110. Ritter W. Pharmacokinetic fundamentals of vaginal treatment with clotrimazole. Am J Obstet Gynecol 152 (1985) 945-947
111. Young G., and Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 4 (2001) CD000225.
112. Davidson F., and Mould R. Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment. Br J Vener Dis 54 (1978) 176-183
113. Fong I. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 68 (1992) 174-176
114. Dennerstein G. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med 31 (1986) 801-803
115. Hilton E., Isenberg H., Alperstein P., France K., and Borenstein M. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 116 (1992) 353-357
116. Rosedale N., and Browne K. Hyposensitisation in the management of recurring vaginal candidiasis. Ann Allergy 43 (1979) 250-253
117. Rigg D., Miller M., and Metzger W. Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 162 (1990) 332-336
118. Mathema B., Cross E., Dun E., et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 33 (2001) E23-E27
119. Sobel J., and Vazquez J. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 22 (1996) 726-727
120. Richter S., Galask R., Messer S., Hollis R., Diekema D., and Pfaller M. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43 (2005) 2155-2162
121. Sobel J., Zervos M., Reed B., et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated candida vaginitis: clinical implications. Antimicrob Agents Chemother 47 (2003) 34-38
122. Moosa M., Sobel J., Elhalis H., Du W., and Akins R. Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium. Antimicrob Agents Chemother 48 (2004) 161-167
123. Sobel J., Chaim W., Nagappan V., and Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 189 (2003) 1297-1300
124. Phillips A. Treatment of non-albicans candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 192 (2005) 2009-2012
125. Shann S., and Wilson J. Treatment of Candida glabrata using topical amphotericin B and flucytosine. Sex Transm Infect 79 (2003) 265-266
126. Walker P., Reynolds M., Ashbee H., Brown C., and Evans E. Vaginal yeasts in the era of "over the counter" antifungals. Sex Transm Infect 76 (2000) 437-438
127. Ferris D., Nyirjesy P., Sobel J., Soper D., Pavletic A., and Litaker M. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 99 (2002) 419-425
128. Klein R., Harris C., Small C., Moll B., Lesser M., and Friedland G. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 311 (1984) 354-358
129. Rhoads J., Wright D., Redfield R., and Burke D. Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA 257 (1987) 3105-3107
130. Carpenter C., Mayer K., Fisher A., Desai M., and Durand L. Natural history of acquired immunodeficiency syndrome in women in Rhode Island. Am J Med 86 (1989) 771-775
131. Leigh J., Barousse M., Swoboda R., et al. Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis 183 (2001) 277-285
132. Schuman P., Sobel J., Ohmit S., et al. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis 27 (1998) 1161-1167
133. Duerr A., Heilig C., Meikle S., et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 101 (2003) 548-556
134. Schuman P., Capps L., Peng G., et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 126 (1997) 689-696
135. Sobel J., Ohmit S., Schuman P., et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 183 (2001) 286-293
136. Vazquez J., Peng G., Sobel J., et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis 33 (2001) 1069-1075
137. Mostad S., Overbaugh J., DeVange D., et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 350 (1997) 922-927
138. Wang C., McClelland R., Reilly M., et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 183 (2001) 1017-1022
139. Petersen K., Matthiesen F., Agger T., et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol 26 (2006) 465-475
140. Aperis G., and Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 15 (2006) 579-602
141. Spellberg B., Ibrahim A., Avanesian V., et al. Efficacy of the anti-candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 194 (2006) 256-260
142. De Bernardis F., Liu H., O'Mahony R., et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 195 (2007) 149-157